1-10 of 10
Roger Dansey, MD
Close
Sort by
Journal Articles

Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability

Jacqueline C. Barrientos, MD, Nina D. Wagner-Johnston, MD, Sven De Vos, MD, PhD, Steven E. Coutre, MD, Marshall T. Schreeder, MD, MPH, Ian Flinn, MD, PhD, Jeff P. Sharman, MD, Kanti R. Rai, MD, John P. Leonard, M.D., Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Henry Adewoye, MD, Richard R. Furman, MD
Journal: Blood
Blood (2013) 122 (21): 4176.
https://doi.org/10.1182/blood.V122.21.4176.4176
Published: 2013
Journal Articles

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Steven E. Coutre, MD, John P. Leonard, MD, Jacqueline C. Barrientos, MD, Sven De Vos, MD, PhD, Ian Flinn, MD, PhD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Nina Wagner-Johnston, MD, Don M. Benson, Jr., MD, PhD, Marshall T. Schreeder, MD, Jeff P. Sharman, MD, Thomas Boyd, MD, Stephen Spurgeon, MD, Andrew D. Zelenetz, MD, PhD, Nicole Lamanna, MD, Thomas J. Kipps, MD, PhD, Brad S. Kahl, MD, Celeste M. Bello, MD, Jan A. Burger, MD, PhD, Kanti R. Rai, MD, Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Mirella Lazarov, PhD, Ronald L. Dubowy, MD, Susan M. O'Brien, MD
Journal: Blood
Blood (2013) 122 (21): 1632.
https://doi.org/10.1182/blood.V122.21.1632.1632
Published: 2013
Journal Articles

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, MD, Sven De Vos, MD, PhD, John P. Leonard, MD, Jacqueline C. Barrientos, MD, Marshall T. Schreeder, MD, Ian W. Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, Nathan Fowler, MD, Kanti R. Rai, MD, Yeonhee Kim, PhD, Leanne M. Holes, Roger Dansey, MD, Thomas M. Jahn, MD, PhD, Steven E. Coutre, MD
Journal: Blood
Blood (2013) 122 (21): 4180.
https://doi.org/10.1182/blood.V122.21.4180.4180
Published: 2013
Journal Articles

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Sarah A Meadows, Huong (Marie) Nguyen, M.D., Christophe Queva, PhD, Brian J. Lannutti, PhD, Adam Kashishian, Susie Jun, MD, PhD, Steven E. Coutre, MD, Roger Dansey, MD, Jason Gotlib, MD, MS
Journal: Blood
Blood (2013) 122 (21): 4065.
https://doi.org/10.1182/blood.V122.21.4065.4065
Published: 2013
Journal Articles

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Sven De Vos, MD, PhD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Nina D. Wagner-Johnston, MD, Ian Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, John P. Leonard, M.D., Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Ronald L. Dubowy, MD, Steven E. Coutre, MD
Journal: Blood
Blood (2013) 122 (21): 2878.
https://doi.org/10.1182/blood.V122.21.2878.2878
Published: 2013
Journal Articles

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Feng Jin, PhD, Huafeng Zhou, PhD, Lorna Fang, Xiaoming Li, PhD, Terry Newcomb, MD, Roger Dansey, MD, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5054.
https://doi.org/10.1182/blood.V122.21.5054.5054
Published: 2013
Journal Articles

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Ajay Gopal, MD, Brad S. Kahl, MD, Sven De Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Kristie A. Blum, MD, Wojciech J. Jurczak, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, PhD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, Leanne M. Holes, Daniel Li, PhD, Roger Dansey, MD, Wayne R. Godfrey, MD, Gilles A. Salles, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 85.
https://doi.org/10.1182/blood.V122.21.85.85
Published: 2013
Journal Articles

Patients with Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy with First and Subsequent Cycle Pegfilgrastim Support Experience Low Rates of Neutropenic Complications: Preliminary Results of FIRST, a Prospective Community-Based Study.

Howard Ozer, MD, PhD, Stephen J. Noga, MD, PhD, Vicki A. Morrison, MD, Beiying Ding, PhD, Roger Dansey, MD
Journal: Blood
Blood (2005) 106 (11): 4705.
https://doi.org/10.1182/blood.V106.11.4705.4705
Published: 2005
Journal Articles

First-Cycle Pegfilgrastim Reduces Chemotherapy-Induced Febrile Neutropenia among Older Patients with NHL Treated in Community Practice: Results from a Large, Randomized, Controlled Trial.

William Ershler, MD, Jennifer Tam, Veena Charu, MD, Ali Ben-Jacob, MD, Seta Shahin, Jeannette Green, Roger Dansey, MD, Lodovico Balducci, MD
Journal: Blood
Blood (2005) 106 (11): 4286.
https://doi.org/10.1182/blood.V106.11.4286.4286
Published: 2005
Journal Articles

Pegfilgrastim (Neulasta®) and Filgrastim (Neupogen®) Use in Patients Receiving Chemotherapy in Oncology Practices: Interim Results of the Assessment of Current CSF Evaluation for Proper Therapy (ACCEPT) Study.

Luis Alberto Meza, MD, Veena Charu, MD, Roger Dansey, MD, Fang Xie, PhD, Bradley Stolshek, PharmD
Journal: Blood
Blood (2004) 104 (11): 5309.
https://doi.org/10.1182/blood.V104.11.5309.5309
Published: 2004